Glioblastoma Program

Our most advanced program is in first line treatment of glioblastoma, a life-threatening cancer of the glial cells in the brain, affecting 28,000 patients worldwide.  GBM is one of the most hypoxic cancers, and this hypoxia causes significant resistance to both radiation and chemotherapy. The average life expectancy post-diagnosis is less than 2 years. The current standard of care is 1) surgery to the extent possible, 2) followed by radiation and chemotherapy with temozolomide.


In our Phase 2 clinical program, we injected TSC 45 minutes prior to radiation or chemo, reducing the treatment resistance caused by the tumor hypoxia and safely producing a 37% increase in overall survival at 2 years and a 4-fold increase in survival in the inoperable patient subset versus controls.

Based on the phase 2 results, we’ve initiated and are enrolling patients in a Phase 3 trial of TSC, which we call the INTACT trial. You’ll hear more about that soon.